When launched, Ingelvac CircoFLEX® was the first PCV2 vaccine that could be freshly mixed with an M hyo vaccine and is still considered one of the most revolutionary PCV2 vaccines on the market. Due to its unique features, it has built a reputation for providing safe, effective control of porcine circovirus associated disease (PCVAD) in pigs three weeks of age or older from a single dose.

Eleven years after launching Ingelvac CircoFLEX®, researchers of Boehringer Ingelheim developed a process, named DiaTEC, within the current outline of production that removes residual cell media components from the VLPs (virus like particles) to obtain a highly immunogenic and non-virucidal vaccine.

The same diafiltration process is also applied in the production of Reprocyc ParvoFLEX, another vaccine from Boehringer Ingelheim that can be mixed with the modified live vaccine Reprocyc PRRS EU which was launched in October 2019.

Eva Joras, Global Brand Manager at Boehringer Ingelheim said, “I am really proud that we continuously invest in our research and development to further improve our leading products to address our customers’ needs.”

The CVMP (Committee for Medicinal Products for Veterinary Use) granted the positive opinion for this type II grouped variation application in May 2019 and as of January 2020 onwards Ingelvac CircoFLEX®, manufactured with the new diafiltration process, DiaTEC, will be launched in several differing packaging sizes.

With this new diafiltration technology, the color of the vaccine has changed to a clear suspension while Ingelvac CircoFLEX retains all of its previous label claims, efficacy and safety profile. To enhance the differentiation of the product at this time, the packaging design has been updated to a more modern and clean design.